Develpmental Therapeutics

发展治疗计划是Karmanos癌症研究所努力开发，理解和测试癌症新疗法的基石。为了实现这一目标，该计划涉及针对特定目标的新化合物的合成以及新鉴定化合物的改进。这些化合物最初使用体外系统和动物模型进行研究，然后由我们的I期小组进行测试。我们开发了新的药物和方法，已经进入临床测试。该计划的第二个要素涉及了解和改善肿瘤对化疗和放疗反应的新方法，其中包括药物药效学研究和对化疗和放疗的分析。 正常组织和肿瘤样品中的药物代谢和耐药性途径。该计划的第三个目标是扩大新的非侵入性成像方法的使用（例如，PET、MRI、超声），用于测量肿瘤生长、灌注和药物动力学。最后，我们正在II期和III期试验中验证我们的新方法。我们的教师进行这项研究的一部分，研究者发起的试验在我们的机构，作为多中心研究的一部分，或在国家试验通过一些合作小组。每一个主题都将临床和基础科学研究人员聚集在一起， 治疗和评估方法。乳腺、人口研究和预防、分子生物学和人类遗传学以及蛋白酶和癌症项目的研究人员正在与发育治疗学的同事沿着合作测试新的治疗方法。在过去的几年里，大量的新治疗方法已经被引入临床，并且更多的治疗方法仍在开发中。该计划的重点是如何加快对每种新疗法的承诺和缺陷的评估，以最终为患者提供最佳的生存机会。

The Developmental Therapeutics Program is the keystone of the Karmanos Cancer Institute's effort to develop, understand, and test new treatments for cancer. To achieve this goal the Program is involved in the synthesis of new compounds directed at specific targets as well as the refinement of newly identified compounds. These compounds are initially studied using in vitro systems and animal models prior to testing by our Phase I group. We have developed new agents and approaches that have already entered clinical testing. A second element of the program involves new approaches to understanding and improving tumor response to chemo- and radiotherapy, which includes studies of drug pharmacodynamics and the analysis of pathways of drug metabolism and resistance in normal tissue and tumor samples. The third aim of the program expands the use of new non-invasive imaging approaches (e.g., PET, MRI, ultrasound) that are being developed to measure tumor growth, perfusion, and drug kinetics. Finally, we are validating our new approaches in Phase II and Phase Ill trials. Our faculty conducts this research as part of investigator initiated trials at our institution, as part of multicenter studies, or in national trials through a number of cooperative groups. Each of these main themes brings clinical and basic science researchers together to produce innovative new therapies and means of assessment. Investigators in the Breast, Population Studies and Prevention, Molecular Biology and Human Genetics, and Proteases and Cancer Programs are collaborating in testing new therapeutic approaches along with colleagues in Developmental Therapeutics. Over the last few years a large number of new treatments have been introduced to the clinic, and a larger number are still in the pipeline. This Program is focused on ways to speed the assessment of the promise and pitfalls of each new therapy to ultimately provide patients with the best possible chance at survival.